From bench to bedside: Future potential for the translation of prolactin inhibitors as breast cancer therapeutics

Journal of Mammary Gland Biology and Neoplasia

Volumn 13, Issue 1, 2008, Pages 147-156

  Clevenger, Charles V ^a   Zheng, Jiamao ^a   Jablonski, Elizabeth M ^a   Galbaugh, Traci L ^a   Fang, Feng ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

Author keywords

Breast cancer; Clinical trials; Pre clinical testing; Prolactin receptor

Indexed keywords

ANTINEOPLASTIC AGENT; BROMOCRIPTINE; CYCLOPHILIN A ANTAGONIST; CYCLOPHILIN B ANTAGONIST; CYCLOSPORIN A; ENDOSTATIN; G 129R; GROWTH HORMONE RECEPTOR ANTAGONIST; HORMONE RECEPTOR BLOCKING AGENT; IMATINIB; INTERLEUKIN 2; ISOPROTEIN; JANUS KINASE 2 ANTAGONIST; PEGVISOMANT; PROLACTIN; PROLACTIN INHIBITOR; PROLACTIN RECEPTOR; PROLACTIN RECEPTOR ANTAGONIST; PROLACTIN RECEPTOR ANTIBODY; PROTEIN NEK3; PROTEIN NEK3 ANTAGONIST; PROTEIN SERINE THREONINE KINASE; S 179D; STAT5 PROTEIN ANTAGONIST; TAMOXIFEN; TRASTUZUMAB; UNCLASSIFIED DRUG;

ACROMEGALY; ARTICLE; BINDING AFFINITY; BREAST CANCER; BREAST CARCINOGENESIS; CANCER CELL; CANCER GROWTH; CANCER INHIBITION; CELL PROLIFERATION; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; DRUG HALF LIFE; DRUG MECHANISM; DRUG POTENTIATION; DRUG RECEPTOR BINDING; DRUG RESEARCH; DRUG SYNTHESIS; HORMONE ACTION; HORMONE DETERMINATION; HORMONE RELEASE; HUMAN; IMMUNE DEFICIENCY; IN VITRO STUDY; IN VIVO STUDY; MONOTHERAPY; NEPHROTOXICITY; NONHUMAN; PROTEIN PHOSPHORYLATION; PROTEIN VARIANT; SIGNAL TRANSDUCTION;

EID: 40249111487     PISSN: 10833021     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10911-008-9074-8     Document Type: Article

References (89)

1. 1. LM Boot 1962 Further investigations on induction of mammary cancer in mice by isografts of hypophyseal tissue Cancer Res 22 713 727 13871149 Boot LM, et al. Further investigations on induction of mammary cancer in mice by isografts of hypophyseal tissue. Cancer Res 1962;22:713–27.
2. 2. LM Boot G Ropcke O Muhlbock 1962 Mammary tumour induction by pituitary isografts in mice Acta Unio Int Contra Cancrum 18 270 271 13871150 Boot LM, Ropcke G, Muhlbock O. Mammary tumour induction by pituitary isografts in mice. Acta Unio Int Contra Cancrum 1962;18:270–1.
3. 3. CW Welsch C Gribler 1973 Prophylaxis of spontaneously developing mammary carcinoma in C3H-HeJ female mice by suppression of prolactin Cancer Res 33 11 2939 2946 4795906 Welsch CW, Gribler C. Prophylaxis of spontaneously developing mammary carcinoma in C3H-HeJ female mice by suppression of prolactin. Cancer Res 1973;33(11):2939–46.
4. 4. CW Welsch H Nagasawa 1977 Prolactin and murine mammary tumorigenesis: a review Cancer Res 37 4 951 963 191183 Welsch CW, Nagasawa H. Prolactin and murine mammary tumorigenesis: a review. Cancer Res 1977;37(4):951–63.
5. 5. JC Heuson A Coune M Staquet 1972 Clinical tial of 2-Br-alpha-Ergocryptine (CB-154) in advanced breast cancer Eur J Cancer 8 155 156 Heuson JC, Coune A, Staquet M. Clinical tial of 2-Br-alpha-Ergocryptine (CB-154) in advanced breast cancer. Eur J Cancer 1972;8:155–6.
6. 6. JP Peyrat 1984 Effect of bromocriptin treatment on prolactin and steroid receptor levels in human breast cancer Eur J Cancer Clin Oncol 20 11 1363 1367 6094194 10.1016/0277-5379(84)90054-3 Peyrat JP, et al. Effect of bromocriptin treatment on prolactin and steroid receptor levels in human breast cancer. Eur J Cancer Clin Oncol 1984;20(11):1363–7.
7. 7. J Bonneterre 1988 Tamoxifen plus bromocriptine versus tamoxifen plus placebo in advanced breast cancer: results of a double blind multicentre clinical trial Eur J Cancer Clin Oncol 24 12 1851 1853 3065085 10.1016/0277-5379(88)90097-1 Bonneterre J, et al. Tamoxifen plus bromocriptine versus tamoxifen plus placebo in advanced breast cancer: results of a double blind multicentre clinical trial. Eur J Cancer Clin Oncol 1988;24(12):1851–3.
8. 8. E Anderson 1993 Serum immunoreactive and bioactive lactogenic hormones in advanced breast cancer patients treated with bromocriptine and octreotide Eur J Cancer 29A 2 209 217 8422285 10.1016/0959-8049(93)90178-I Anderson E, et al. Serum immunoreactive and bioactive lactogenic hormones in advanced breast cancer patients treated with bromocriptine and octreotide. Eur J Cancer 1993;29A(2):209–17.
9. 9. CV Clevenger 2003 The role of prolactin in mammary carcinoma Endocr Rev 24 1 1 27 12588805 10.1210/er.2001-0036 1:CAS:528:DC%2BD3sXhslOgsb8%3D Clevenger CV, et al. The role of prolactin in mammary carcinoma. Endocr Rev 2003;24(1):1–27.
10. 10. CV Clevenger 2003 Role of prolactin/prolactin receptor signaling in human breast cancer Breast Dis 18 75 86 15687690 Clevenger CV. Role of prolactin/prolactin receptor signaling in human breast cancer. Breast Dis 2003;18:75–86.
11. 11. ME Lippman 1977 In vitro model systems for the study of hormone-dependent human breast cancer N Engl J Med 296 3 154 159 187935 10.1056/NEJM197701202960307 Lippman ME, et al. In vitro model systems for the study of hormone-dependent human breast cancer. N Engl J Med 1977;296(3):154–9.
12. 12. E Ginsburg BK Vonderhaar 1995 Prolactin synthesis and secretion by human breast cancer cells Cancer Res 55 12 2591 2595 7780973 Ginsburg E, Vonderhaar BK. Prolactin synthesis and secretion by human breast cancer cells. Cancer Res 1995;55(12):2591–5.
13. 13. MV Maus SC Reilly CV Clevenger 1999 Prolactin as a chemoattractant for human breast carcinoma Endocrinology 140 11 5447 5450 10537179 10.1210/en.140.11.5447 Maus MV, Reilly SC, Clevenger CV. Prolactin as a chemoattractant for human breast carcinoma. Endocrinology 1999;140(11):5447–50.
14. 14. CM Perks 2004 Prolactin acts as a potent survival factor for human breast cancer cell lines Br J Cancer 91 2 305 311 15213724 Perks CM, et al. Prolactin acts as a potent survival factor for human breast cancer cell lines. Br J Cancer 2004;91(2):305–11.
15. 15. R Das BK Vonderhaar 1997 Prolactin as a mitogen in mammary cells J Mammary Gland Biol Neoplasia 2 1 29 39 10887517 10.1023/A:1026369412612 Das R, Vonderhaar BK. Prolactin as a mitogen in mammary cells. J Mammary Gland Biol Neoplasia 1997;2(1):29–39.
16. 16. J Mershon 1995 Prolactin is a local growth factor in rat mammary tumors Endocrinology 136 8 3619 3623 7628401 10.1210/en.136.8.3619 Mershon J, et al. Prolactin is a local growth factor in rat mammary tumors. Endocrinology 1995;136(8):3619–23.
17. 17. LM Arendt 2006 Prolactin potentiates transforming growth factor alpha induction of mammary neoplasia in transgenic mice Am J Pathol 168 4 1365 1374 16565509 10.2353/ajpath.2006.050861 1:CAS:528:DC%2BD28XjslOhu7s%3D Arendt LM, et al. Prolactin potentiates transforming growth factor alpha induction of mammary neoplasia in transgenic mice. Am J Pathol 2006;168(4):1365–74.
18. 18. TA Rose-Hellekant 2003 Prolactin induces ERalpha-positive and ERalpha-negative mammary cancer in transgenic mice Oncogene 22 30 4664 4674 12879011 10.1038/sj.onc.1206619 1:CAS:528:DC%2BD3sXls1Gjt7g%3D Rose-Hellekant TA, et al. Prolactin induces ERalpha-positive and ERalpha-negative mammary cancer in transgenic mice. Oncogene 2003;22(30):4664–74.
19. 19. H Wennbo J Tornell 2000 The role of prolactin and growth hormone in breast cancer Oncogene 19 8 1072 1076 10713692 10.1038/sj.onc.1203349 1:CAS:528:DC%2BD3cXitVegsrw%3D Wennbo H, Tornell J. The role of prolactin and growth hormone in breast cancer. Oncogene 2000;19(8):1072–6.
20. 20. H Wennbo 1997 Activation of the prolactin receptor but not the growth hormone receptor is important for induction of mammary tumors in transgenic mice J Clin Invest 100 11 2744 2751 9389738 Wennbo H, et al. Activation of the prolactin receptor but not the growth hormone receptor is important for induction of mammary tumors in transgenic mice. J Clin Invest 1997;100(11):2744–51.
21. 21. SR Oakes 2007 Loss of mammary epithelial prolactin receptor delays tumor formation by reducing cell proliferation in low-grade preinvasive lesions Oncogene 26 4 543 553 16862169 10.1038/sj.onc.1209838 1:CAS:528:DC%2BD2sXoslSjtg%3D%3D Oakes SR, et al. Loss of mammary epithelial prolactin receptor delays tumor formation by reducing cell proliferation in low-grade preinvasive lesions. Oncogene 2007;26(4):543–53.
22. 22. G Fuh 1992 Rational design of potent antagonists to the human growth hormone receptor Science 256 5064 1677 1680 1535167 10.1126/science.256.5064.1677 Fuh G, et al. Rational design of potent antagonists to the human growth hormone receptor. Science 1992;256(5064):1677–80.
23. 23. V Goffin 1994 Evidence for a second receptor binding site on human prolactin J Biol Chem 269 51 32598 32606 7798264 Goffin V, et al. Evidence for a second receptor binding site on human prolactin. J Biol Chem 1994;269(51):32598–606.
24. 24. S Bernichtein 2003 Development of pure prolactin receptor antagonists J Biol Chem 278 38 35988 35999 12824168 10.1074/jbc.M305687200 1:CAS:528:DC%2BD3sXnt1aqtb0%3D Bernichtein S, et al. Development of pure prolactin receptor antagonists. J Biol Chem 2003;278(38):35988–99.
25. 25. TJ Chen 1998 Development of recombinant human prolactin receptor antagonists by molecular mimicry of the phosphorylated hormone Endocrinology 139 2 609 616 9449632 10.1210/en.139.2.609 Chen TJ, et al. Development of recombinant human prolactin receptor antagonists by molecular mimicry of the phosphorylated hormone. Endocrinology 1998;139(2):609–16.
26. 26. YN Sinha 1995 Structural variants of prolactin: occurrence and physiological significance Endocr Rev 16 3 354 369 7671851 10.1210/er.16.3.354 Sinha YN. Structural variants of prolactin: occurrence and physiological significance. Endocr Rev 1995;16(3):354–69.
27. 27. WS Oetting 1986 Phosphorylation of prolactin J Biol Chem 261 4 1649 1652 3003080 Oetting WS, et al. Phosphorylation of prolactin. J Biol Chem 1986;261(4):1649–52.
28. 28. AM Walker 2007 S179D prolactin: Antagonistic agony Mol Cell Endocrinol 276 1–2 1 9 17669587 10.1016/j.mce.2007.06.001 1:CAS:528:DC%2BD2sXpvFGks74%3D Walker AM. S179D prolactin: Antagonistic agony. Mol Cell Endocrinol 2007;276(1–2):1–9.
29. 29. TW Ho 1993 Secretion of specific nonphosphorylated and phosphorylated rat prolactin isoforms at different stages of the estrous cycle Neuroendocrinology 58 2 160 165 8264862 Ho TW, et al. Secretion of specific nonphosphorylated and phosphorylated rat prolactin isoforms at different stages of the estrous cycle. Neuroendocrinology 1993;58(2):160–5.
30. 30. K Horiguchi 2007 Estrogen regulates the serum level of phosphorylated prolactin in mice J Reprod Dev 53 4 915 922 17558189 10.1262/jrd.18158 Horiguchi K, et al. Estrogen regulates the serum level of phosphorylated prolactin in mice. J Reprod Dev 2007;53(4):915–22.
31. 31. PT Tuazon 2002 p21-activated protein kinase gamma-PAK in pituitary secretory granules phosphorylates prolactin FEBS Lett 515 1–3 84 88 11943200 10.1016/S0014-5793(02)02444-4 Tuazon PT, et al. p21-activated protein kinase gamma-PAK in pituitary secretory granules phosphorylates prolactin. FEBS Lett 2002;515(1–3):84–8.
32. 32. YF Wang AM Walker 1993 Dephosphorylation of standard prolactin produces a more biologically active molecule: evidence for antagonism between nonphosphorylated and phosphorylated prolactin in the stimulation of Nb2 cell proliferation Endocrinology 133 5 2156 2160 8404666 10.1210/en.133.5.2156 Wang YF, Walker AM. Dephosphorylation of standard prolactin produces a more biologically active molecule: evidence for antagonism between nonphosphorylated and phosphorylated prolactin in the stimulation of Nb2 cell proliferation. Endocrinology 1993;133(5):2156–60.
33. 33. JR Wicks CL Brooks 1995 Biological activity of phosphorylated and dephosphorylated bovine prolactin Mol Cell Endocrinol 112 2 223 229 7489826 10.1016/0303-7207(95)03604-6 Wicks JR, Brooks CL. Biological activity of phosphorylated and dephosphorylated bovine prolactin. Mol Cell Endocrinol 1995;112(2):223–9.
34. 34. W Wu 2005 S179D prolactin increases vitamin D receptor and p21 through up-regulation of short 1b prolactin receptor in human prostate cancer cells Cancer Res 65 16 7509 7515 16103106 10.1158/0008-5472.CAN-04-3350 Wu W, et al. S179D prolactin increases vitamin D receptor and p21 through up-regulation of short 1b prolactin receptor in human prostate cancer cells. Cancer Res 2005;65(16):7509–15.
35. 35. X Xu 2001 A molecular mimic of phosphorylated prolactin markedly reduced tumor incidence and size when DU145 human prostate cancer cells were grown in nude mice Cancer Res 61 16 6098 6104 11507059 Xu X, et al. A molecular mimic of phosphorylated prolactin markedly reduced tumor incidence and size when DU145 human prostate cancer cells were grown in nude mice. Cancer Res 2001;61(16):6098–104.
36. 36. MJ Naylor 2005 Transcriptional changes underlying the secretory activation phase of mammary gland development Mol Endocrinol 19 7 1868 1883 15705664 10.1210/me.2004-0254 1:CAS:528:DC%2BD2MXlvFSku78%3D Naylor MJ, et al. Transcriptional changes underlying the secretory activation phase of mammary gland development. Mol Endocrinol 2005;19(7):1868–83.
37. 37. S Bernichtein 2001 S179D-human PRL, a pseudophosphorylated human PRL analog, is an agonist and not an antagonist Endocrinology 142 9 3950 3963 11517174 10.1210/en.142.9.3950 1:CAS:528:DC%2BD3MXmsFSgsL4%3D Bernichtein S, et al. S179D-human PRL, a pseudophosphorylated human PRL analog, is an agonist and not an antagonist. Endocrinology 2001;142(9):3950–63.
38. 38. MD Schroeder 2003 Inhibition of prolactin (PRL)-induced proliferative signals in breast cancer cells by a molecular mimic of phosphorylated PRL, S179D-PRL Endocrinology 144 12 5300 5307 12970160 10.1210/en.2003-0826 1:CAS:528:DC%2BD3sXpsV2gtbg%3D Schroeder MD, et al. Inhibition of prolactin (PRL)-induced proliferative signals in breast cancer cells by a molecular mimic of phosphorylated PRL, S179D-PRL. Endocrinology 2003;144(12):5300–7.
39. 39. V Goffin 2005 Development and potential clinical uses of human prolactin receptor antagonists Endocr Rev 26 3 400 422 15814850 10.1210/er.2004-0016 1:CAS:528:DC%2BD2MXltVWru7k%3D Goffin V, et al. Development and potential clinical uses of human prolactin receptor antagonists. Endocr Rev 2005;26(3):400–22.
40. 40. AM Vos de M Ultsch AA Kossiakoff 1992 Human growth hormone and extracellular domain of its receptor: crystal structure of the complex Science 255 5042 306 312 1549776 10.1126/science.1549776 de Vos AM, Ultsch M, Kossiakoff AA. Human growth hormone and extracellular domain of its receptor: crystal structure of the complex. Science 1992;255(5042):306–12.
41. 41. W Somers 1994 The X-ray structure of a growth hormone-prolactin receptor complex Nature 372 6505 478 481 7984244 10.1038/372478a0 Somers W, et al. The X-ray structure of a growth hormone-prolactin receptor complex. Nature 1994;372(6505):478–81.
42. 42. SL Gadd CV Clevenger 2006 Ligand-independent dimerization of the human prolactin receptor isoforms: functional implications Mol Endocrinol 20 11 2734 2746 16840534 10.1210/me.2006-0114 1:CAS:528:DC%2BD28XhtFymsb7N Gadd SL, Clevenger CV. Ligand-independent dimerization of the human prolactin receptor isoforms: functional implications. Mol Endocrinol 2006;20(11):2734–46.
43. 43. RJ Brown 2005 Model for growth hormone receptor activation based on subunit rotation within a receptor dimer Nat Struct Mol Biol 12 9 814 821 16116438 10.1038/nsmb977 1:CAS:528:DC%2BD2MXpslaqtLo%3D Brown RJ, et al. Model for growth hormone receptor activation based on subunit rotation within a receptor dimer. Nat Struct Mol Biol 2005;12(9):814–21.
44. 44. V Goffin 1996 Sequence–function relationships within the expanding family of prolactin, growth hormone, placental lactogen, and related proteins in mammals Endocr Rev 17 4 385 410 8854051 10.1210/er.17.4.385 Goffin V, et al. Sequence–function relationships within the expanding family of prolactin, growth hormone, placental lactogen, and related proteins in mammals. Endocr Rev 1996;17(4):385–410.
45. 45. WL Miller NL Eberhardt 1983 Structure and evolution of the growth hormone gene family Endocr Rev 4 2 97 130 6345149 10.1210/edrv-4-2-97 Miller WL, Eberhardt NL. Structure and evolution of the growth hormone gene family. Endocr Rev 1983;4(2):97–130.
46. 46. WY Chen 1999 A human prolactin antagonist, hPRL-G129R, inhibits breast cancer cell proliferation through induction of apoptosis Clin Cancer Res 5 11 3583 3593 10589775 Chen WY, et al. A human prolactin antagonist, hPRL-G129R, inhibits breast cancer cell proliferation through induction of apoptosis. Clin Cancer Res 1999;5(11):3583–93.
47. 47. P Ramamoorthy 2001 In vitro studies of a prolactin antagonist, hPRL-G129R in human breast cancer cells Int J Oncol 18 1 25 32 11115535 Ramamoorthy P, et al. In vitro studies of a prolactin antagonist, hPRL-G129R in human breast cancer cells. Int J Oncol 2001;18(1):25–32.
48. 48. MT Beck SK Peirce WY Chen 2002 Regulation of bcl-2 gene expression in human breast cancer cells by prolactin and its antagonist, hPRL-G129R Oncogene 21 33 5047 5055 12140755 10.1038/sj.onc.1205637 1:CAS:528:DC%2BD38XlsFWrs7k%3D Beck MT, Peirce SK, Chen WY. Regulation of bcl-2 gene expression in human breast cancer cells by prolactin and its antagonist, hPRL-G129R. Oncogene 2002;21(33):5047–55.
49. 49. L Cataldo 2000 Inhibition of oncogene STAT3 phosphorylation by a prolactin antagonist, hPRL-G129R, in T-47D human breast cancer cells Int J Oncol 17 6 1179 1185 11078803 Cataldo L, et al. Inhibition of oncogene STAT3 phosphorylation by a prolactin antagonist, hPRL-G129R, in T-47D human breast cancer cells. Int J Oncol 2000;17(6):1179–85.
50. 50. JF Langenheim 2006 Two wrongs can make a right: dimers of prolactin and growth hormone receptor antagonists behave as agonists Mol Endocrinol 20 3 661 674 16269515 10.1210/me.2005-0360 1:CAS:528:DC%2BD28Xit1Snsbw%3D Langenheim JF, et al. Two wrongs can make a right: dimers of prolactin and growth hormone receptor antagonists behave as agonists. Mol Endocrinol 2006;20(3):661–74.
51. 51. NY Chen 2002 In vivo studies of the anti-tumor effects of a human prolactin antagonist, hPRL-G129R Int J Oncol 20 4 813 818 11894130 Chen NY, et al. In vivo studies of the anti-tumor effects of a human prolactin antagonist, hPRL-G129R. Int J Oncol 2002;20(4):813–8.
52. 52. S Tomblyn 2005 The role of human prolactin and its antagonist, G129R, in mammary gland development and DMBA-initiated tumorigenesis in transgenic mice Int J Oncol 27 5 1381 1389 16211235 Tomblyn S, et al. The role of human prolactin and its antagonist, G129R, in mammary gland development and DMBA-initiated tumorigenesis in transgenic mice. Int J Oncol 2005;27(5):1381–9.
53. 53. SK Peirce WY Chen 2004 Human prolactin and its antagonist, hPRL-G129R, regulate bax and bcl-2 gene expression in human breast cancer cells and transgenic mice Oncogene 23 6 1248 1255 14647416 10.1038/sj.onc.1207245 1:CAS:528:DC%2BD2cXhtlWntbo%3D Peirce SK, Chen WY. Human prolactin and its antagonist, hPRL-G129R, regulate bax and bcl-2 gene expression in human breast cancer cells and transgenic mice. Oncogene 2004;23(6):1248–55.
54. 54. M Llovera 2000 Human prolactin (hPRL) antagonists inhibit hPRL-activated signaling pathways involved in breast cancer cell proliferation Oncogene 19 41 4695 4705 11032019 10.1038/sj.onc.1203846 1:CAS:528:DC%2BD3cXns1ehsrg%3D Llovera M, et al. Human prolactin (hPRL) antagonists inhibit hPRL-activated signaling pathways involved in breast cancer cell proliferation. Oncogene 2000;19(41):4695–705.
55. 55. G Fuh 1993 Mechanism-based design of prolactin receptor antagonists J Biol Chem 268 8 5376 5381 8449901 Fuh G, et al. Mechanism-based design of prolactin receptor antagonists. J Biol Chem 1993;268(8):5376–81.
56. 56. S Bernichtein 2003 New homologous bioassays for human lactogens show that agonism or antagonism of various analogs is a function of assay sensitivity Endocrine 20 1–2 177 190 12668884 10.1385/ENDO:20:1-2:177 Bernichtein S, et al. New homologous bioassays for human lactogens show that agonism or antagonism of various analogs is a function of assay sensitivity. Endocrine2003;20(1–2):177–90.
57. 57. A Mode 1996 The human growth hormone (hGH) antagonist G120RhGH does not antagonize GH in the rat, but has paradoxical agonist activity, probably via the prolactin receptor Endocrinology 137 2 447 454 8593788 10.1210/en.137.2.447 Mode A, et al. The human growth hormone (hGH) antagonist G120RhGH does not antagonize GH in the rat, but has paradoxical agonist activity, probably via the prolactin receptor. Endocrinology 1996;137(2):447–54.
58. 58. PA Elkins 2000 Ternary complex between placental lactogen and the extracellular domain of the prolactin receptor Nat Struct Biol 7 9 808 815 10966654 10.1038/79047 1:CAS:528:DC%2BD3cXmsFWksrk%3D Elkins PA, et al. Ternary complex between placental lactogen and the extracellular domain of the prolactin receptor. Nat Struct Biol 2000;7(9):808–15.
59. 59. JB Jomain 2007 Structural and thermodynamical bases for the design of pure prolactin receptor antagonists. X-ray structure of Del1-9-G129R-hPRL J Biol Chem. 282 33118 33131 17785459 10.1074/jbc.M704364200 1:CAS:528:DC%2BD2sXht1Clur%2FE Jomain JB, et al. Structural and thermodynamical bases for the design of pure prolactin receptor antagonists. X-ray structure of Del1-9-G129R-hPRL. J Biol Chem. 2007;282:33118–31.
60. 60. V Goffin 2003 Development of new prolactin analogs acting as pure prolactin receptor antagonists Pituitary 6 2 89 95 14703018 10.1023/B:PITU.0000004799.41035.9f Goffin V, et al. Development of new prolactin analogs acting as pure prolactin receptor antagonists. Pituitary 2003;6(2):89–95.
61. 61. S Kinet 1999 Biological properties of human prolactin analogs depend not only on global hormone affinity, but also on the relative affinities of both receptor binding sites J Biol Chem 274 37 26033 26043 10473550 10.1074/jbc.274.37.26033 Kinet S, et al. Biological properties of human prolactin analogs depend not only on global hormone affinity, but also on the relative affinities of both receptor binding sites. J Biol Chem 1999;274(37):26033–43.
62. 62. G Zhang 2002 A novel design of targeted endocrine and cytokine therapy for breast cancer Clin Cancer Res 8 4 1196 1205 11948133 Zhang G, et al. A novel design of targeted endocrine and cytokine therapy for breast cancer. Clin Cancer Res 2002;8(4):1196–205.
63. 63. Y Yokoyama 2000 Effect of endostatin on spontaneous tumorigenesis of mammary adenocarcinoma in a transgenic mouse model Cancer Res 60 16 4362 4365 10969778 Yokoyama Y, et al. Effect of endostatin on spontaneous tumorigenesis of mammary adenocarcinoma in a transgenic mouse model. Cancer Res 2000;60(16):4362–5.
64. 64. MT Beck 2003 Prolactin antagonist–endostatin fusion protein as a targeted dual-functional therapeutic agent for breast cancer Cancer Res 63 13 3598 3604 12839947 Beck MT, et al. Prolactin antagonist–endostatin fusion protein as a targeted dual-functional therapeutic agent for breast cancer. Cancer Res 2003;63(13):3598–604.
65. 65. JF Langenheim WY Chen 2005 Development of a prolactin receptor-targeting fusion toxin using a prolactin antagonist and a recombinant form of Pseudomonas exotoxin A Breast Cancer Res Treat 90 3 281 293 15830142 10.1007/s10549-004-4816-9 1:CAS:528:DC%2BD2MXjt1Wgtb0%3D Langenheim JF, Chen WY. Development of a prolactin receptor-targeting fusion toxin using a prolactin antagonist and a recombinant form of Pseudomonas exotoxin A. Breast Cancer Res Treat 2005;90(3):281–93.
66. 66. C Vogel 2001 First-line, single-agent Herceptin(R) (trastuzumab) in metastatic breast cancer. a preliminary report Eur J Cancer 37 Suppl 1 25 29 11342197 10.1016/S0959-8049(00)00405-6 Vogel C, et al. First-line, single-agent Herceptin(R) (trastuzumab) in metastatic breast cancer. a preliminary report. Eur J Cancer 2001;37(Suppl 1):25–9.
67. 67. JF Sissom ML Eigenbrodt JC Porter 1988 Anti-growth action on mouse mammary and prostate glands of a monoclonal antibody to prolactin receptor Am J Pathol 133 3 589 595 2462356 Sissom JF, Eigenbrodt ML, Porter JC. Anti-growth action on mouse mammary and prostate glands of a monoclonal antibody to prolactin receptor. Am J Pathol 1988;133(3):589–95.
68. 68. T Hunter 2007 Treatment for chronic myelogenous leukemia: the long road to imatinib J Clin Invest 117 8 2036 2043 17671637 10.1172/JCI31691 1:CAS:528:DC%2BD2sXoslOgurc%3D Hunter T. Treatment for chronic myelogenous leukemia: the long road to imatinib. J Clin Invest 2007;117(8):2036–43.
69. 69. L DaSilva 1994 Growth signaling and JAK2 association mediated by membrane-proximal cytoplasmic regions of prolactin receptors J Biol Chem 269 28 18267 18270 8034567 DaSilva L, et al. Growth signaling and JAK2 association mediated by membrane-proximal cytoplasmic regions of prolactin receptors. J Biol Chem 1994;269(28):18267–70.
70. 70. H Rui RA Kirken WL Farrar 1994 Activation of receptor-associated tyrosine kinase JAK2 by prolactin J Biol Chem 269 7 5364 5368 7508935 Rui H, Kirken RA, Farrar WL. Activation of receptor-associated tyrosine kinase JAK2 by prolactin. J Biol Chem 1994;269(7):5364–8.
71. 71. L Li PE Shaw 2002 Autocrine-mediated activation of STAT3 correlates with cell proliferation in breast carcinoma lines J Biol Chem 277 20 17397 17405 11859072 10.1074/jbc.M109962200 1:CAS:528:DC%2BD38XktVCgsbc%3D Li L, Shaw PE. Autocrine-mediated activation of STAT3 correlates with cell proliferation in breast carcinoma lines. J Biol Chem 2002;277(20):17397–405.
72. 72. WM Burke 2001 Inhibition of constitutively active Stat3 suppresses growth of human ovarian and breast cancer cells Oncogene 20 55 7925 7934 11753675 10.1038/sj.onc.1204990 1:CAS:528:DC%2BD3MXptlKku7Y%3D Burke WM, et al. Inhibition of constitutively active Stat3 suppresses growth of human ovarian and breast cancer cells. Oncogene 2001;20(55):7925–34.
73. 73. SL Miller 2005 Novel association of Vav2 and Nek3 modulates signaling through the human prolactin receptor Mol Endocrinol 19 4 939 949 15618286 10.1210/me.2004-0443 1:CAS:528:DC%2BD2MXjtVCjsr0%3D Miller SL, et al. Novel association of Vav2 and Nek3 modulates signaling through the human prolactin receptor. Mol Endocrinol 2005;19(4):939–49.
74. 74. SL Miller 2007 Nek3 kinase regulates prolactin-mediated cytoskeletal reorganization and motility of breast cancer cells Oncogene 26 32 4668 4678 17297458 10.1038/sj.onc.1210264 1:CAS:528:DC%2BD2sXnsFOis74%3D Miller SL, et al. Nek3 kinase regulates prolactin-mediated cytoskeletal reorganization and motility of breast cancer cells. Oncogene 2007;26(32):4668–78.
75. 75. F Syed 2003 A novel and functional interaction between cyclophilin A and prolactin receptor Endocrine 20 1–2 83 90 12668872 10.1385/ENDO:20:1-2:83 Syed F, et al. A novel and functional interaction between cyclophilin A and prolactin receptor. Endocrine 2003;20(1–2):83–90.
76. 76. MA Rycyzyn CV Clevenger 2000 Role of cyclophilins in somatolactogenic action Ann N Y Acad Sci 917 514 521 11268379 10.1111/j.1749-6632.2000.tb05416.x Rycyzyn MA, Clevenger CV. Role of cyclophilins in somatolactogenic action. Ann N Y Acad Sci 2000;917:514–21.
77. 77. MA Rycyzyn CV Clevenger 2002 The intranuclear prolactin/cyclophilin B complex as a transcriptional inducer Proc Natl Acad Sci U S A 99 10 6790 6795 11997457 10.1073/pnas.092160699 1:CAS:528:DC%2BD38XjvFCrt7Y%3D Rycyzyn MA, Clevenger CV. The intranuclear prolactin/cyclophilin B complex as a transcriptional inducer. Proc Natl Acad Sci U S A 2002;99(10):6790–5.
78. 78. MA Rycyzyn 2000 Role of cyclophilin B in prolactin signal transduction and nuclear retrotranslocation Mol Endocrinol 14 8 1175 1186 10935542 10.1210/me.14.8.1175 Rycyzyn MA, et al. Role of cyclophilin B in prolactin signal transduction and nuclear retrotranslocation. Mol Endocrinol 2000;14(8):1175–86.
79. 79. RJ Bram 1993 Identification of the immunophilins capable of mediating inhibition of signal transduction by cyclosporin A and FK506: roles of calcineurin binding and cellular location Mol Cell Biol 13 8 4760 4769 7687744 Bram RJ, et al. Identification of the immunophilins capable of mediating inhibition of signal transduction by cyclosporin A and FK506: roles of calcineurin binding and cellular location. Mol Cell Biol 1993;13(8):4760–9.
80. 80. RJ Bram GR Crabtree 1994 Calcium signalling in T cells stimulated by a cyclophilin B-binding protein Nature 371 6495 355 358 7522304 10.1038/371355a0 Bram RJ, Crabtree GR. Calcium signalling in T cells stimulated by a cyclophilin B-binding protein. Nature 1994;371(6495):355–8.
81. 81. T Stewart 1995 Incidence of de-novo breast cancer in women chronically immunosuppressed after organ transplantation Lancet 346 8978 796 798 7674744 10.1016/S0140-6736(95)91618-0 Stewart T, et al. Incidence of de-novo breast cancer in women chronically immunosuppressed after organ transplantation. Lancet 1995;346(8978):796–8.
82. 82. M Gschwendt W Kittstein F Marks 1988 The weak immunosuppressant cyclosporine D as well as the immunologically inactive cyclosporine H are potent inhibitors in vivo of phorbol ester TPA-induced biological effects in mouse skin and of Ca2 +/calmodulin dependent EF-2 phosphorylation in vitro Biochem Biophys Res Commun 150 2 545 551 3342035 10.1016/0006-291X(88)90428-7 Gschwendt M, Kittstein W, Marks F. The weak immunosuppressant cyclosporine D as well as the immunologically inactive cyclosporine H are potent inhibitors in vivo of phorbol ester TPA-induced biological effects in mouse skin and of Ca2 +/calmodulin dependent EF-2 phosphorylation in vitro. Biochem Biophys Res Commun 1988;150(2):545–51.
83. 83. J Yang 2005 Novel roles of unphosphorylated STAT3 in oncogenesis and transcriptional regulation Cancer Res 65 3 939 947 15705894 Yang J, et al. Novel roles of unphosphorylated STAT3 in oncogenesis and transcriptional regulation. Cancer Res 2005;65(3):939–47.
84. 84. S Ren 2002 Loss of Stat5a delays mammary cancer progression in a mouse model Oncogene 21 27 4335 4339 12082622 10.1038/sj.onc.1205484 1:CAS:528:DC%2BD38XkslKmt7g%3D Ren S, et al. Loss of Stat5a delays mammary cancer progression in a mouse model. Oncogene 2002;21(27):4335–9.
85. 85. N Jing DJ Tweardy 2005 Targeting Stat3 in cancer therapy Anticancer Drugs 16 6 601 607 15930886 10.1097/00001813-200507000-00002 Jing N, Tweardy DJ. Targeting Stat3 in cancer therapy. Anticancer Drugs 2005;16(6):601–7.
86. 86. N Jing 2003 Targeting Stat3 with G-quartet oligodeoxynucleotides in human cancer cells DNA Cell Biol 22 11 685 696 14659041 10.1089/104454903770946665 1:CAS:528:DC%2BD3sXptlelsL0%3D Jing N, et al. Targeting Stat3 with G-quartet oligodeoxynucleotides in human cancer cells. DNA Cell Biol 2003;22(11):685–96.
87. 87. ES Schernhammer 2006 Insulin-like growth factor-I, its binding proteins (IGFBP-1 and IGFBP-3), and growth hormone and breast cancer risk in The Nurses Health Study II Endocr Relat Cancer 13 2 583 592 16728584 10.1677/erc.1.01149 1:CAS:528:DC%2BD28XntF2mtbs%3D Schernhammer ES, et al. Insulin-like growth factor-I, its binding proteins (IGFBP-1 and IGFBP-3), and growth hormone and breast cancer risk in The Nurses Health Study II. Endocr Relat Cancer 2006;13(2):583–92.
88. 88. KK Kaulsay 2001 The effects of autocrine human growth harmone (GH) on human mammary cell behavior are mediated via the hGH receptor. Endocrinol 142 767 777 10.1210/en.142.2.767 Kaulsay KK, et al. The effects of autocrine human growth hormone (GH) on human mammary cell behavior are mediated via the hGH receptor. Endocrinol 2001;142:767–777.
89. 89. J Divisova 2006 The growth hormone antagonist pegvisomant blocks both mammary gland development and MCF-7 breast cancer xenograft growth. Breast Ca Res Treat 98 315 327 10.1007/s10549-006-9168-1 1:CAS:528:DC%2BD28XnvVGmu7k%3D Divisova J, et al. The growth hormone antagonist pegvisomant blocks both mammary gland development and MCF-7 breast cancer xenograft growth. Breast Ca Res Treat 2006;98:315–327.